Pathogenesis of NASH and Promising Natural Products

被引:28
作者
Leng Ying-Rong
Zhang Mei-Hui
Luo Jian-Guang [1 ]
Zhang Hao [1 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Sch Tradit Chinese Pharm, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
NASH; Natural medicine; Animal model; Target; Pathogenesis; FATTY LIVER-DISEASE; FARNESOID-X-RECEPTOR; CHOLINE-DEFICIENT DIET; HEPATIC STEATOSIS; NONALCOHOLIC STEATOHEPATITIS; OXIDATIVE STRESS; INSULIN-RESISTANCE; METABOLIC SYNDROME; ANIMAL-MODELS; INTESTINAL MICROBIOTA;
D O I
10.1016/S1875-5364(21)60002-X
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Nonalcoholic steatohepatitis (NASH) is a common clinical condition that can lead to advanced liver diseases. The mechanism of the diaease progression, which is lacking effective therapy, remains obsure. Therefore, there is a need to understand the pathogenic mechanisms responsible for disease development and progression in order to develop innovative therapies. To accomplish this goal, experimental animal models that recapitulate the human disease are necessary. Currently, an increasing number of studies have focused on natural constituents from medicinal plants which have been emerged as a new hope for NASH. This review summarized the pathogenesis of NASH, animal models commonly used, and the promising targets for therapeutics. We also reviewed the natural constituents as potential NASH therapeutic agents.
引用
收藏
页码:12 / 27
页数:16
相关论文
共 155 条
[1]   Withaferin A Protects Against High-Fat Diet-Induced Obesity Via Attenuation of Oxidative Stress, Inflammation, and Insulin Resistance [J].
Abu Bakar, Mohamad Hafizi ;
Azmi, Mohamad Nurul ;
Shariff, Khairul Anuar ;
Tan, Joo Shun .
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2019, 188 (01) :241-259
[2]   Non-alcoholic fatty liver disease [J].
Angulo, P ;
Lindor, KD .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 :S186-S190
[3]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[4]   Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease [J].
Angulo, Paul ;
Kleiner, David E. ;
Dam-Larsen, Sanne ;
Adams, Leon A. ;
Bjornsson, Einar S. ;
Charatcharoenwitthaya, Phunchai ;
Mills, Peter R. ;
Keach, Jill C. ;
Lafferty, Heather D. ;
Stahler, Alisha ;
Haflidadottir, Svanhildur ;
Bendtsen, Flemming .
GASTROENTEROLOGY, 2015, 149 (02) :389-+
[5]   Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis [J].
Awad, Azza S. M. ;
Abd Al Haleem, Ekram N. ;
El-Bakly, Wesam M. ;
Sherief, Mohie A. .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (04) :381-391
[6]   An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity [J].
Babaknejad, Nasim ;
Nayeri, Hashem ;
Hemmati, Roohullah ;
Bahrami, Somaye ;
Esmaillzadeh, Ahmad .
HORMONE AND METABOLIC RESEARCH, 2018, 50 (06) :441-452
[7]   Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats [J].
Bagul, Pankaj K. ;
Middela, Harish ;
Matapally, Saidulu ;
Padiya, Raju ;
Bastia, Tanmay ;
Madhusudana, K. ;
Reddy, B. Raghunath ;
Chakravarty, Sumana ;
Banerjee, Sanjay K. .
PHARMACOLOGICAL RESEARCH, 2012, 66 (03) :260-268
[8]   Extracellular matrix degradation and the role of hepatic stellate cells [J].
Benyon, RC ;
Arthur, MJP .
SEMINARS IN LIVER DISEASE, 2001, 21 (03) :373-384
[9]   Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice [J].
Berres, Marie-Luise ;
Koenen, Rory R. ;
Rueland, Anna ;
Zaldivar, Mirko Moreno ;
Heinrichs, Daniel ;
Sahin, Hacer ;
Schmitz, Petra ;
Streetz, Konrad L. ;
Berg, Thomas ;
Gassler, Nikolaus ;
Weiskirchen, Ralf ;
Proudfoot, Amanda ;
Weber, Christian ;
Trautwein, Christian ;
Wasmuth, Hermann E. .
JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (11) :4129-4140
[10]   Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes [J].
Birkenfeld, Andreas L. ;
Shulman, Gerald I. .
HEPATOLOGY, 2014, 59 (02) :713-723